WEIFANG, SHANDONG, CHINA, January 21, 2026 /EINPresswire.com/ -- 1. Rising Global Demand for PDT LED Light Therapy As ...
The FDA accepted the supplemental new drug application (sNDA) for aminolevulinic acid hydrochloride 10% topical gel (Ameluz) as part of photodynamic therapy (PDT) for superficial basal cell carcinoma ...
US FDA acknowledges no filing deficiencies in Biofrontera’s sNDA for Ameluz PDT in superficial basal cell carcinoma: Woburn, Massachusetts Saturday, February 14, 2026, 16:00 Hrs ...
Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first ...
A new publication from Opto-Electronic Advances; DOI 10.29026/oea.2024.240013, discusses a NIR-triggered on-site NO/ROS/RNS nanoreactor. Phototherapy is a safe and effective method for tumor treatment ...
WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Recently, the team of Academician Xiaojun Peng from Dalian University of Technology, Associate Professor Haidong Li, and the team of Professor Juyoung Yoon from Ewha Womans University, South Korea ...
Though SE was the most effective therapy for Bowen disease, the risk for recurrence with 5-FU and MAL-PDT was negligible.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results